2 results
Approved WMOCompleted
Primary: efficacy and safety of the addition of UMEC 62.5mcg once daily to ICS/LABA therapy, compared with placebo over 12 weeks in subjects with COPD.Secondary: effect of the addition of UMEC to ICS/LABA therapy on COPD-related health status…
Approved WMOPending
Primary Objective: test the feasibility of Dynamic-CE-MRI using Ablavar ® as contrast agent to detect peritoneal endometriosis in women.Secondary Objective(s): # To assess the image quality of Ablavar ®-enhanced MRI in comparison to unenhanced MRI…